Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03019549 · ClinicalTrials.gov registry record · Phase 1
A Study of Lanabecestat (LY3314814) in Healthy Participants When Taken With Rosuvastatin
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
NCT03019549 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 42 participants.
The verdict
NCT03019549, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effect of lanabecestat on rosuvastatin. The amount of rosuvastatin in the blood will be compared, when taken alone, and then when taken with lanabecestat. The amount of lanabecestat that gets into the bloodstream will be measured. Information about any side effects that may occur will also be collected. Participants will be on study for 21 days with a follow-up at least 7 days afterwards. Screening will be undertaken within 45 days prior to enrollment.
Interventions
- DRUG Rosuvastatin
- DRUG Lanabecestat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2017-01-12 |
| Est. Completion | 2017-05-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03019549
The ClinicalTrials.gov registry entry for NCT03019549 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rosuvastatin is the first listed.
NCT03019549 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03019549 about?
NCT03019549 is a clinical study titled "A Study of Lanabecestat (LY3314814) in Healthy Participants When Taken With Rosuvastatin". The purpose of this study is to evaluate the effect of lanabecestat on rosuvastatin. The amount of rosuvastatin in the blood will be compared, when taken alone, and then when taken with lanabecestat. The amount of lanabecestat that gets into the bloodstream will be measured. Information about any si...
What is the current status of trial NCT03019549?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2017-01-12. Estimated completion is 2017-05-22.
What interventions are being tested in trial NCT03019549?
The interventions under investigation include: Rosuvastatin (DRUG), Lanabecestat (DRUG).
Who is sponsoring clinical trial NCT03019549?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.